Dr. Sammy S. Datwani is an influential senior executive, entrepreneur, and innovative technology leader with a demonstrated history of developing emergent technologies and commercializing disruptive revolutionary life science tools and microfluidic device products. Dr. Datwani has over 20 years of executive and leadership experience
building teams and developing solutions that allow customers to meet their biotechnology research and commercial objectives in the fields of microfluidics, laboratory automation, genomics, proteomics, analytical chemistry, molecular diagnostics, synthetic biology, and cell engineering.
Dr. Datwani serves on the Board of Directors for AmplifiDx, Visicell Medical Inc., as a Scientific Advisory Board member to Basilard Biotechnologies, an Equity Partner at WING VC, on the Board of Directors for the Life Science Angels (LSA) group; on non-profit boards for the Society of Laboratory Automation & Screening (SLAS), and his almamater, The Johns Hopkins University, Whiting School of Engineering. Dr. Datwani served on the Board of Directors for COMBiNATi Inc., (a digital PCR company acquired by Thermo Fisher Scientific). He is an invited mentor for the National Academy Engineering Covid-19 Crisis. Dr. Datwani has also served as an expert witness for a high-profile patent litigation case.
His current and recent roles include Vice President, Development – Synthego Corporation, a venture-backed startup. President – SSD Advisors, LLC., a consultancy firm. Head of Technology Development – Inscripta Inc., a venture-backed startup., Sr. Director, R& D, Principal Scientist at Labcyte Inc. which was acquired by Beckman Coulter Life Sciences (a Danaher company), Eksigent Technologies, acquired by Sciex (a Danaher company) and Caliper Life Sciences (IPO, and acquisition by Perkin Elmer).
Dr. Datwani is an author and inventor on numerous scientific publications and patents and is actively involved with scientific programming at international meetings and
conferences. Dr. Datwani received his B.S. (with honors) and Ph.D. in chemical and biomolecular engineering from the Johns Hopkins University, Baltimore, MD, and his M.S. in chemical engineering from Columbia University, New York, New York.
Dr. Datwani was inducted to the College of Fellows of the American Institute of Medical
and Biological Engineers (AIMBE) for his contributions to leveraging microscale phenomena to enable label-free and high-throughput experimentation, screening and precision medicine (see https://aimbe.org/college-of-fellows/cof-3029/).